Skip to content
10-Q

Quarterly Report

BioNexus Gene Lab Corp. BGLC

0001477932-26-003242

← back to feed
Filed
May 15, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 15, 2026 2.42M sh
Shares Diluted Q1 2026 · Mar 31, 2026 2.42M sh
Shares Diluted restated Q1 2026 · Mar 31, 2025 1.8M sh
Capex Q1 2026 · Mar 31, 2026 $325
Capex Q1 2026 · Mar 31, 2025 $9.05K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$147.67K
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$824.07K
Stockholders Equity Q1 2026 · Mar 31, 2026 $8.09M
Stockholders Equity Q1 2026 · Dec 31, 2025 $8.61M
Stockholders Equity Q1 2026 · Mar 31, 2025 $7.77M
Stockholders Equity Q1 2026 · Dec 31, 2024 $8.32M
Current Liabilities Q1 2026 · Mar 31, 2026 $796.47K
Current Liabilities Q1 2026 · Dec 31, 2025 $520.96K
Total Liabilities Q1 2026 · Mar 31, 2026 $946.88K
Total Liabilities Q1 2026 · Dec 31, 2025 $637.86K
Current Assets Q1 2026 · Mar 31, 2026 $5.2M
Current Assets Q1 2026 · Dec 31, 2025 $5.45M
Total Assets Q1 2026 · Mar 31, 2026 $9.04M
Total Assets Q1 2026 · Dec 31, 2025 $9.25M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.23
Eps Diluted restated Q1 2026 · Mar 31, 2025 −$0.35
Sga Expense Q1 2026 · Mar 31, 2026 $327.67K
Sga Expense Q1 2026 · Mar 31, 2025 $391.88K
Rd Expense Q1 2026 · Mar 31, 2026 $14.49K
Rd Expense Q1 2026 · Mar 31, 2025 $12.14K
Net Income Q1 2026 · Mar 31, 2026 −$543.58K
Net Income Q1 2026 · Mar 31, 2025 −$623.33K
Operating Income Q1 2026 · Mar 31, 2026 −$540.49K
Operating Income Q1 2026 · Mar 31, 2025 −$618.42K
Gross Profit Q1 2026 · Mar 31, 2026 −$790
Gross Profit Q1 2026 · Mar 31, 2025 $343.49K
Cost Of Revenue Q1 2026 · Mar 31, 2026 $23.63K
Cost Of Revenue Q1 2026 · Mar 31, 2025 $1.79M
Revenue Q1 2026 · Mar 31, 2026 $22.84K
Revenue Q1 2026 · Mar 31, 2025 $2.14M